Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 411 | 60 | 343 |
| Samples | 130 | 27 | 99 |
| Peptides | 119 | 19 | 100 |
Function
CPSF4 · Cleavage and polyadenylation specific factor 4
Inhibition of the nuclear export of poly(A)-containing mRNAs caused by the influenza A virus NS1 protein requires its effector domain. The NS1 effector domain functionally interacts with the cellular 30 kDa subunit of cleavage and polyadenylation specific factor 4, an essential component of the 3' end processing machinery of cellular pre-mRNAs. In influenza virus-infected cells, the NS1 protein is physically associated with cleavage and polyadenylation specific factor 4, 30kD subunit. Binding of the NS1 protein to the 30 kDa protein in vitro prevents CPSF binding to the RNA substrate and inhibits 3' end cleavage and polyadenylation of host pre-mRNAs. Thus the NS1 protein selectively inhibits the nuclear export of cellular, and not viral, mRNAs. Multiple alternatively spliced transcript variants that encode different isoforms have been described for this gene. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
6 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 84 amino-acid changes on canonical ENST00000292476 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CPSF4 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CPSF4 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Endometrial Carcinoma | 2/42 5% | 7/612 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Bladder Carcinoma | 1/58 2% | 8/956 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Colorectal Carcinoma | 9/143 6% | 15/3239 0% |
| Gastric Carcinoma | 2/74 3% | 11/1809 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Esophageal Carcinoma | 0/23 0% | 5/769 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 4/810 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Biliary Tract Carcinoma | 0/54 0% | 4/950 0% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
| Non-Small Cell Lung Carcinoma | 2/304 1% | 4/1390 0% |
| Melanoma | 0/210 0% | 7/1899 0% |
| Other Solid Cancers | 0/94 0% | 5/1515 0% |
| Ovarian Carcinoma | 2/109 2% | 1/998 0% |
| Hepatocellular Carcinoma | 0/46 0% | 5/2210 0% |
| Breast Carcinoma | 2/144 1% | 5/3264 0% |
| Non-Cancerous | 0/104 0% | 2/830 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 1/752 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 2/2550 0% |
| Pancreatic Carcinoma | 0/89 0% | 2/1611 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 2/1592 0% |
| Other Blood Cancers | 1/61 2% | 2/2725 0% |
| Kidney Carcinoma | 0/85 0% | 2/1862 0% |
| Glioma | 0/52 0% | 2/2127 0% |
| Prostate Carcinoma | 2/13 15% | 0/2105 0% |
Mutation Distribution
Where CPSF4 is mutated · all tissues, split by cell line vs tissue
How many mutations in CPSF4 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 411 mutations in CPSF4
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|